Evidence map›Paper›PMID 36353214›Full record

ArticleFrontiers in bioinformatics2022

Bioinformatics Approaches to Predict Mutation Effects in the Binding Site of the Proangiogenic Molecule CD93.

Vittoria Cicaloni, Malancha Karmakar, Luisa Frusciante, Francesco Pettini, Anna Visibelli, Maurizio Orlandini, Federico Galvagni, Maurizio Mongiat, Michael Silk, Federica Nardi and 3 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in bioinformatics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Vittoria CicaloniToscana Life Sciences Foundation, Siena, Italy.
Malancha KarmakarStructural Biology and Bioinformatics, Department of Biochemistry, University of Melbourne, Parkville, VIC, Australia.
Luisa FruscianteDepartment of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy.
Francesco PettiniDepartment of Medical Biotechnologies, University of Siena, Siena, Italy.
Anna VisibelliDepartment of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy.
Maurizio OrlandiniDepartment of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy.
Federico GalvagniDepartment of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy.
Maurizio MongiatDepartment of Research and Diagnosis, Division Molecular Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.
Michael SilkStructural Biology and Bioinformatics, Department of Biochemistry, University of Melbourne, Parkville, VIC, Australia.
Federica NardiDepartment of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy.
David AscherStructural Biology and Bioinformatics, Department of Biochemistry, University of Melbourne, Parkville, VIC, Australia.
Annalisa SantucciDepartment of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy.
Ottavia SpigaDepartment of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy.
University of Siena · ITBaker Heart and Diabetes Institute · AUCentro di Riferimento Oncologico · ITToscana Life Sciences · ITUniversity of Melbourne · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The transmembrane glycoprotein CD93 has been identified as a potential new target to inhibit tumor angiogenesis. Recently, Multimerin-2 (MMRN2), a pan-endothelial extracellular matrix protein, has been identified as a ligand for CD93, but the interaction mechanism between these two proteins is yet to be studied. In this article, we aim to investigate the structural and functional effects of induced mutations on the binding domain of CD93 to MMRN2. Starting from experimental data, we assessed how specific mutations in the C-type lectin-like domain (CTLD) affect the binding interaction profile. We described a four-step workflow in order to predict the effects of variations on the inter-residue interaction network at the PPI, based on evolutionary information, complex network metrics, and energetic affinity. We showed that the application of computational approaches, combined with experimental data, allowed us to gain more in-depth molecular insights into the CD93-MMRN2 interaction, offering a platform for developing innovative therapeutics able to target these molecules and block their interaction. This comprehensive molecular insight might prove useful in drug design in cancer therapy.

Indexed as

angiogenesisbioinformaticsCD93computation biologymultimerin

Identifiers

PMID36353214
PMCPMC9638713
OpenAlexW4283205042

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.